Boletín de AInvest
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
On March 25, 2025, Bausch Health's stock price dropped by 10.45% in pre-market trading.
Bausch Health reported strong fourth-quarter earnings and revenue, with Xifaxan contributing significantly to sales growth. The company's earnings per share (EPS) for the quarter were $1.21, indicating robust financial performance.
Bausch Health has announced the conditional redemption of its outstanding 5.500% Senior Notes, a move that could impact its financial structure and investor sentiment.
Northwest & Ethical Investments L.P. significantly increased its holdings in
, reflecting confidence in the company's future prospects. Similarly, Charles Schwab Investment Management Inc. also boosted its position in the company's shares.
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Comentarios
Aún no hay comentarios